Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients.

Related Links:

No abstract available

Source: Oncology TimesCategory: Cancer & Oncology Tags: News Source Type: research

Cytarabine (ara-C) is a well-established agent widely used for treating AML. Conventionally, it is combined with anthracyclines for treating newly diagnosed Acute Myeloid Leukaemia (AML). At higher doses it is combined with the purine analogue fludarabine plus idarubicin and G-CSF (FLAG-Ida) for the treatment of relapsed or refractory AML. Fludarabine is known to potentiate intracellular accumulation of the active cytotoxic metabolite ara-CTP from ara-C via inhibition of ribonucleotide reductase and the normal formation of endogenous dCTP [1], and removal of the inhibition of deoxycytidine kinase (dCK) by dCTP [2,3].

Source: Leukemia ResearchCategory: Hematology Authors: Source Type: research

Condition:   Acute Myeloid Leukemia (AML) Interventions:   Drug: Venetoclax;   Drug: Gilteritinib Sponsors:   AbbVie;   Astellas Pharma Inc;   Genentech, Inc. Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Conclusion: Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.Cell Physiol Biochem 2018;48:2061 –2073

Despite recent advances in the management of subpopulations of AML, overall outcomes remain unsatisfactory. Encouraging results were seen with alvocidib (formerly known as flavopiridol), a CDK9 inhibitor with pan-cyclin-dependent kinase (CDK) activity, followed by cytarabine and mitoxantrone (FLAM) in serial phase I-II studies in newly diagnosed AML patients [1 –7]. Therefore, we conducted a randomized phase II clinical trial comparing FLAM to cytarabine and daunorubicin (7 + 3) in newly diagnosed AML patients 18-70 years of age with non-favorable risk cytogenetics [8].

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Letter to the Editor Source Type: research

Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia (AML) in the World Health Organization classification [1]. APMF is characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly [2 –5]. A standard treatment has not been established for APMF. Treatment modalities for APMF have considerable heterogeneity, including chemotherapies such as danazol, lenalidomide, and zoledronate [2,3,6,7]. However, such treatments have limited efficacy and the vast majority of patients will die f rom progressive disease, such as bone marrow failure and development of overt AML.

Source: Biology of Blood and Marrow TransplantationCategory: Hematology Authors: Tags: Brief Article Source Type: research

Conditions:   FLT3-ITD Mutation;   AML Intervention:   Drug: Sorafenib Sponsor:   The University of Hong Kong Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.

Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report of Berlin-Frankfurt-Münster study group.
Haematologica. 2018 Aug 09;:
Authors: Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M
Abstract
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia have poor survival. We evaluated Gemtuzumab Ozogamicin (CD33-targeted drug) used on compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia-Berlin-F…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

o M, Martinez-Lopez J, Ayala R
Abstract
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease (MRD) negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for MRD assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-SNVs. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by NGS, evaluating the level of mutations detected at diagnosis. The predictive value of MRD status by NGS, multipa…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image